SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,055.50 |
| Enterprise Value ($M) | 2,027.89 |
| Book Value ($M) | 275.19 |
| Book Value / Share | 7.99 |
| Price / Book | 7.47 |
| NCAV ($M) | 271.21 |
| NCAV / Share | 7.88 |
| Price / NCAV | 7.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.27 |
| Return on Assets (ROA) | -1.30 |
| Return on Equity (ROE) | -1.47 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 15.97 |
| Current Ratio | 15.97 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 293.03 |
| Assets | 297.00 |
| Liabilities | 21.82 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Cormorant Asset Management, LP | 8.10 | 30.30 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 7.50 | 78.81 | |
| 13G/A | Vanguard Group Inc | 5.22 | 0.00 | |
| 13G | BlackRock, Inc. | 8.30 | 0.00 | |
| 13G/A | Farallon Capital Partners, L.P. | 9.99 | 56.67 | |
| 13G/A | Fmr Llc | 11.18 | -3.47 | |
| 13G | Viking Global Investors Lp | 5.20 | ||
| 13G/A | Point72 Asset Management, L.P. | 3.80 | -34.00 | |
| 13G/A | Prosight Management, LP | 0.00 | -100.00 | |
| 13G/A | HBM Healthcare Investments (Cayman) Ltd. | 0.00 | -100.00 | |
| 13D/A | Pfizer Inc | 0.00 | -100.00 | |
| 13G/A | Integrated Core Strategies (us) Llc | 0.00 | -99.33 | |
| 13G | Ra Capital Management, L.p. | 8.70 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 48,571 | 434,071 | 11.19 | |
| 59,551 | 1,161,012 | 5.13 | |
| 51,023 | 866,444 | 5.89 | |
| 31,593 | 556,171 | 5.68 | |
| 47,349 | 868,773 | 5.45 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KOD – Kodiak Sciences Inc. | KROS – Keros Therapeutics, Inc. |
| KYMR – Kymera Therapeutics, Inc. | LGND – Ligand Pharmaceuticals Incorporated |
| LNTH – Lantheus Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io